Low-grade oligodendroglioma: current treatments and future hopes

References

• Mason WP, Cairncross JG. The expanding impact of molecular biology on the diagnosis and treatment of gliomas. Neurology71, 365–373 (2008).
   PubMed Web of Science ®Google Scholar
• Kleihues P, Cavanee W. Pathology and Genetics of Tumours of the Nervous System. IARC Press, Lyon, France (2000).
   Google Scholar
• Walker DG, Kaye AH. Low grade glial neoplasms. J. Clin. Neurosci.10(1), 1–13 (2003).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Agulnik M, Mason WP. The changing management of low-grade astrocytomas and oligodendrogliomas. Hematol. Oncol. Clin. North Am.20(6), 1249–1266 (2006).
   PubMed Web of Science ®Google Scholar
• Ashby LS, Shapiro WR. Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults. Curr. Neurol. Neurosci. Rep.4(3), 211–217 (2004).
   PubMedGoogle Scholar
• Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology54(7), 1442–1448 (2000).
   PubMed Web of Science ®Google Scholar
• Lebrun C, Fontaine D, Ramaioli A et al. Long-term outcome of oligodendrogliomas. Neurology62(10), 1783–1787 (2004).
   PubMed Web of Science ®Google Scholar
• Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol.61(3), 215–225 (2002).
   PubMed Web of Science ®Google Scholar
• Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer79(7), 1381–1393 (1997).
   PubMed Web of Science ®Google Scholar
• Sepulveda Sanchez JM, Martinez Montero JC, Diez-Lobato R et al. Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival – clinical, radiological and pathologic long-term follow-up analysis. Clin. Neuropathol.28(1), 11–20 (2009).
   PubMed Web of Science ®Google Scholar
• Hart MN, Petito CK, Earle KM. Mixed gliomas. Cancer33, 134–140 (1974).
   PubMed Web of Science ®Google Scholar
• Kim L, Hochberg FH, Thornton AF et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J. Neurosurg.85(4), 602–607 (1996).
   PubMed Web of Science ®Google Scholar
• Mork S, Halvorsen T, Lindegaard K, Eide G. Oligodendroglioma. Histologic evaluation and prognosis. J. Neuropathol. Exp. Neurol. (45), 65–78 (1986).
   PubMed Web of Science ®Google Scholar
• Mork SJ, Lindegaard KF, Halvorsen TB et al. Oligodendroglioma: incidence and biological behavior in a defined population. J. Neurosurg.63(6), 881–889 (1985).
   PubMed Web of Science ®Google Scholar
• Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol.145(5), 1175–1190 (1994).
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Nicolardi L, Demopoulos A et al. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J. Neurooncol.88(3), 293–298 (2008).
   PubMed Web of Science ®Google Scholar
• Walker C, du Plessis DG, Fildes D et al. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin. Cancer Res.10(21), 7182–7191 (2004).
   PubMed Web of Science ®Google Scholar
• Adamson DC, Broderick DK, Di C et al. Genetic analysis of LOH of chromosome 1p, 19q and PIK3CA mutations in oligodendrogliomas. AACR Meeting Abstracts 2005 (1), D659–D660 (2005).
   Google Scholar
• Chan R, Kocialkowski S, Pearson D, Collins VP, Ichimura K. High resolution array-CGH reveals novel homozygous deletions at PTPRD in oligodendrogliomas. AACR Meeting Abstracts (2008) (Abstract 1684).
   Google Scholar
• Walker C, Haylock B, Husband D et al. Molecular genetics and response to PCV chemotherapy in previously untreated oligodendroglial neoplasms. AACR Meeting Abstracts 2005 (1), (2005) (Abstract 507).
   Google Scholar
• Buckner JC, Ballman KV, Scheithauer BW et al. NCCTG 94-72-53: diagnostic and prognostic significance of 1p and 19q deletions in patients (pts) with low-grade oligodendroglioma and astrocytoma. J. Clin. Oncol.23(16 Suppl.), (2005) (Abstract 1502).
   Google Scholar
• Jenkins RB, Blair H, Ballman KV et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res.66(20), 9852–9861 (2006).
   PubMed Web of Science ®Google Scholar
• Bagchi A, Papazoglu C, Francis D, Bradley A, Mills AA. Identification and functional characterization of a novel tumor suppressor region at human 1p36. AACR Meeting Abstracts (1), (2006) (Abstract C609).
   Google Scholar
• Dunlap SM, McDonald JM, Fuller GN et al. The putative tumor suppressor Shrew-1 gene on chromosome 1p36 inhibits adhesion and migration of glioma cells. AACR Meeting Abstracts 2005 (1), (2005) (Abstract A680).
   Google Scholar
• Walker C, du Plessis DG, Joyce KA et al. Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann. Neurol.57(6), 855–865 (2005).
   PubMed Web of Science ®Google Scholar
• Campbell B, Horsman D, Maguire J et al. Chromosomal alterations in oligodendroglial tumors over multiple surgeries: is progression associated with change in 1p/19q status? J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 10577).
   Google Scholar
• Johnson NV, Connelly JJ, Virigadamo J et al. Characterizing oligodendroglioma rearrangements using whole genome hrCGH arrays. AACR Meeting Abstracts 2006 (1), (2006) (Abstract B36).
   Google Scholar
• Holmes K, Dunlap S, Cogdell D, Chow C-W, Fuller G, Zhang W. Integrin-linked kinase contributes to glioma progression in a glial-specific transgenic mouse model. AACR Meeting Abstracts (2008) (Abstract 2909).
   Google Scholar
• Dunlap S, Holmes K, Cogdell D, Chow C-W, Fuller G, Zhang W. Integrin binding is essential for IGFBP2-driven glioma progression. AACR Meeting Abstracts (2008) (Abstract 1969).
   Google Scholar
• Dong SM, Pang JC, Poon WS et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J. Neuropathol. Exp. Neurol.60(8), 808–816 (2001).
   PubMed Web of Science ®Google Scholar
• Mollemann M, Wolter M, Felsberg J et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int. J. Cancer113(3), 379–385 (2005).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Cavallo G et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J. Clin. Oncol.24(29), 4746–4753 (2006).
   PubMed Web of Science ®Google Scholar
• Mikkelsen T, Doyle T, Anderson J et al. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J. Neurooncol.92(1), 57–63 (2009).
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA, Berkey B, Peereboom D et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol.11(2), 167–175 (2009).
   PubMed Web of Science ®Google Scholar
• Nicolardi L, Bertorelle R, Bonaldi L et al. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and relation to 1p/19q loss in low grade gliomas: A GICNO study. J. Clin. Oncol.24(18 Suppl.), (2006) (Abstract 20064).
   Google Scholar
• Wick Wolfgang W, Weller M. Randomized Phase III study of sequential radiochemotherapy of oligoastrocytic tumors of WHO-grade III with PCV or temozolomide: NOA-04. J. Clin. Oncol.26(15 Suppl.), (2008) (Abstract LBA2007).
   Google Scholar
• Hegi ME, Liu L, Herman JG et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol.26(25), 4189–4199 (2008).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens A-C, Gorlia T et al.MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Ashby LS, Pueschel JK, Scheck AC, Coons SW, Shapiro WR. Prognostic factors for patients with newly diagnosed low-grade oligodendroglial tumors: molecular genetics, histopathology, and neuroimaging. J. Clin. Oncol.23(16 Suppl.), (2005) (Abstract 1501).
   Google Scholar
• Prayson RA, Castilla EA, Hembury TA, Liu W, Noga CM, Prok AL. Interobserver variability in determining MIB-1 labeling indices in oligodendrogliomas. Ann. Diagn. Pathol.7(1), 9–13 (2003).
   PubMedGoogle Scholar
• Maiuri F, Del Basso De Caro ML, Iaconetta G, Peca C, Esposito M, de Divitiis E. Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas. Zentralbl. Neurochir.67(4), 204–209 (2006).
   PubMedGoogle Scholar
• Van den Bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. Crit. Rev. Oncol. Hematol.66(3), 262–272 (2008).
   PubMed Web of Science ®Google Scholar
• Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group trial 9402. J. Clin. Oncol.24(18), 2707–2714 (2006).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol.24(18), 2715–2722 (2006).
   PubMed Web of Science ®Google Scholar
• Soffietti R, Ruda R, Trevisan E et al. Temozolomide (TMZ) 1 week on/1 week off as initial treatment for progressive low grade oligodendroglial tumors: a Phase II AINO study. J. Clin. Oncol.26(15 Suppl.), (2008) (Abstract 2019).
   Google Scholar
• El-Hateer H, Souhami L, Roberge D et al. Low-grade oligodendroglioma: an indolent but incurable disease? J. Neurosurg.111(2), 265–271 (2009).
   PubMed Web of Science ®Google Scholar
• The German Glioma Network, Weller M, Berger H et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin. Cancer Res.13(23), 6933–6937 (2007).
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Di Patre P, Burkhard C, Horstmann S, Jourde B, Fahey M. Population based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol.108, 49–56 (2004).
   PubMed Web of Science ®Google Scholar
• See S-J, Gilbert MR. Chemotherapy in adults with gliomas. Ann. Acad. Med. Singapore36(5), 364–366 (2007).
   PubMed Web of Science ®Google Scholar
• Law M, Oh S, Johnson G et al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery58(6), 1099–1107 (2006).
   PubMed Web of Science ®Google Scholar
• Brown R, Zlatescu M, Sijben A et al. The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin. Cancer Res.14(8), 2357–2362 (2008).
   PubMed Web of Science ®Google Scholar
• Norden AD, Wen PY. Glioma therapy in adults. Neurologist12(6), 279–292 (2006).
   PubMed Web of Science ®Google Scholar
• Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J. Clin. Oncol.24(8), 1236–1245 (2006).
   PubMed Web of Science ®Google Scholar
• Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J. Neurosurg.95(5), 735–745 (2001).
   PubMed Web of Science ®Google Scholar
• Leighton C, Fisher B, Bauman G et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J. Clin. Oncol.15(4), 1294–1301 (1997).
   PubMed Web of Science ®Google Scholar
• Claus EB, Horlacher A, Hsu L et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer103(6), 1227–1233 (2005).
   PubMed Web of Science ®Google Scholar
• Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer74(6), 1784–1791 (1994).
   PubMed Web of Science ®Google Scholar
• Smith JS, Chang EF, Lamborn KR et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J. Clin. Oncol.26(8), 1338–1345 (2008).
   PubMed Web of Science ®Google Scholar
• Scerrati M, Roselli R, Iacoangeli M. Prognostic factors in low-grade WHO grade II gliomas of cerebral hemispheres: the role of surgery. J. Neurol. Neurosurg. Psychiatry, (61), 291–296 (1996).
   PubMed Web of Science ®Google Scholar
• Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quiñones-Hinojosa A. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J. Neurosurg. DOI: 10.3171/2008.10.JNS08608 (2009) (Epub ahead of print).
   Google Scholar
• Shaw EG. The low-grade glioma debate: evidence defending the position of early radiation therapy. Clin. Neurosurg.42, 488–494 (1995).
   PubMedGoogle Scholar
• Mason WP. Progress in clinical neurosciences: advances in the management of low-grade gliomas. Can. J. Neurol. Sci.32(1), 18–26 (2005).
   PubMed Web of Science ®Google Scholar
• Kortmann R-D. Radiotherapy in low-grade gliomas: pros. Semin. Oncol.30(Suppl. 19), 29–33 (2003).
   PubMedGoogle Scholar
• Engelhard HH. Current diagnosis and treatment of oligodendroglioma. Neurosurg. Focus12(2), E2 (2002).
   Google Scholar
• Stieber VW. Low-grade gliomas. Curr. Treat. Options Oncol.2(6), 495–506 (2001).
   PubMedGoogle Scholar
• Surma-aho O, Niemela M, Vilkki J et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology56(10), 1285–1290 (2001).
   PubMed Web of Science ®Google Scholar
• Douw L, Klein M, Fagel SS et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol.8(9), 810–818 (2009).
   PubMed Web of Science ®Google Scholar
• Karim AB, Afra D, Cornu P et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BRO4: an interim analysis. Int. J. Radiat. Oncol. Biol. Phys.52(2), 316–324 (2002).
   PubMed Web of Science ®Google Scholar
• Fisher B, Leighton C, Macdonald D, Stitt L, Bauman G, Cairncross G. The dose–volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection. J. Neurooncol.82, 165–170 (2007).
   PubMed Web of Science ®Google Scholar
• Karim AB, Maat B, Hatlevoll R et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int. J. Radiat. Oncol. Biol. Phys.36(3), 549–556 (1996).
   PubMed Web of Science ®Google Scholar
• Shaw E, Arusell R, Scheithauer B et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment group/Radiation Therapy Oncology group/Eastern Cooperative Oncology group study. J. Clin. Oncol.20(9), 2267–2276 (2002).
   PubMed Web of Science ®Google Scholar
• Smith JS, Chang EF, Lamborn KR et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J. Clin. Oncol.26(8), 1338–1345 (2008).
   PubMed Web of Science ®Google Scholar
• Jeremic B, Milicic B, Grujicic D et al. Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma: a 10 year update of a Phase II study. Int. J. Radiat. Oncol. Biol. Phys.57, 465–471 (2003).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ. Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. Semin. Oncol.30(Suppl. 19), 39–44 (2003).
   PubMedGoogle Scholar
• Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology46(1), 203–207 (1996).
   PubMed Web of Science ®Google Scholar
• Eyre HJ, Crowley JJ, Townsend JJ et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J. Neurosurg.78(6), 909–914 (1993).
   PubMed Web of Science ®Google Scholar
• Buckner JC, Gesme D Jr, O’Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J. Clin. Oncol.21(2), 251–255 (2003).
   PubMed Web of Science ®Google Scholar
• Shaw EG, Wang M, Coons S et al. Final report of radiation therapy oncology group (RTOG) protocol 9802: radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). J. Clin. Oncol.26(15 Suppl.), (2008) (Abstract 2006).
   PubMedGoogle Scholar
• Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int. J. Cancer113(3), 379–385 (2005).
   PubMed Web of Science ®Google Scholar
• Lesser GJ. Chemotherapy of low-grade gliomas. Semin. Radiat. Oncol.11(2), 138–144 (2001).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ. Chemotherapy of oligodendroglial tumours: current developments. Forum Trends Exp. Clin. Med.10(2), 108–118 (2000).
   Google Scholar
• van den Bent MJ, Hegi ME, Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur. J. Cancer42(5), 582–588 (2006).
   PubMed Web of Science ®Google Scholar
• Brada M, Viviers L, Abson C et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann. Oncol.14(12), 1715–1721 (2003).
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol.22(15), 3133–3138 (2004).
   PubMed Web of Science ®Google Scholar
• Pace A, Vidiri A, Galie E et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann. Oncol.14(12), 1722–1726 (2003).
   PubMed Web of Science ®Google Scholar
• Quinn JA, Reardon DA, Friedman AH et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J. Clin. Oncol.21(4), 646–651 (2003).
   PubMed Web of Science ®Google Scholar
• Kesari S, Schiff D, Drappatz J et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin. Cancer Res.15(1), 330–337 (2009).
   PubMed Web of Science ®Google Scholar
• Pouratian N, Gasco J, Sherman J, Shaffrey M, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J. Neurooncol.82(3), 281–288 (2007).
   PubMed Web of Science ®Google Scholar
• Schiff D, Brown PD, Giannini C. Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology69(13), 1366–1373 (2007).
   PubMed Web of Science ®Google Scholar